Results 271 to 280 of about 1,252,602 (328)
Global trends of big data analytics in health research: a bibliometric study. [PDF]
Yao L +8 more
europepmc +1 more source
An Analytical Key to Some of the Segregates of Oenothera
R. Ruggles Gates
openalex +2 more sources
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
VISTA: A Visual Analytics Framework to Enhance Foundation Model-Generated Data Labels. [PDF]
Xuan X +6 more
europepmc +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
AI applications in disaster governance with health approach: A scoping review. [PDF]
Kolivand P +6 more
europepmc +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care. [PDF]
Bokemeyer C +10 more
europepmc +1 more source
Modern Analytical Jurisprudence and the Limits of Its Usefulness
Édgar Bodenheimer
openalex +2 more sources

